AngioDynamics, Inc. (ANGO) announced the FDA has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism. The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of pulmonary embolism. The company said the indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function.
The AlphaVac F1885 System is an emergent first-line device that is currently cleared for the removal of thromboemboli from the venous system and for the treatment of pulmonary embolism.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.